Full-Time
R&D Technician
Updated on 8/23/2026
Integer Holdings Corporation
1,001-5,000 employees
Medical device CDMO for cardiac devices
Compensation Overview
$26.57 - $38.98/hr
Plymouth, MN, USA
In Person
Associate's
 Biology & Biotech (1) |
|---|
Get referred to Integer Holdings Corporation
See people who can refer or advise you
- An Associate’s degree in a technical field with 3-5 years of relevant experience, or high school graduation with 7-10 years of relevant experience.
- Ability to read technical drawings and prints.
- Computer operation skills.
- Mechanical aptitude.
- Excellent written and verbal organizational and communication skills.
- Adhere to Integer Core Beliefs and all safety and quality requirements.
- Complete early project builds that do not have defined processes, settings, or instructions.
- Work with engineers to develop production processes and determine settings.
- Write instructions and train personnel in proper techniques for using systems, equipment, and processes.
- Set up and run experiments and test apparatus with direction.
- Design, recommend, assemble, and install equipment, apparatus, and processes for product fabrication, research and development, or analysis and testing.
- Troubleshoot and, when needed, repair, modify, or maintain systems and equipment.
- Provide input in evaluating equipment and processes.
- Write technical reports and other required documentation.
- Interact with and advise other departments.
- Perform other functions as required.
- Product knowledge is helpful.
- Experience building medical catheters is highly preferred.
Integer Holdings Corporation is a large medical device contract development and manufacturing organization (CDMO) that supports medical device makers in cardiac rhythm management, neuromodulation, and cardiovascular markets. It provides end-to-end services from design support to manufacturing, delivering components and finished subsystems such as implants, housings, electrodes, and batteries through its Greatbatch Medical, Lake Region Medical, and Electrochem brands. The company differentiates itself by its scale, breadth of capabilities across multiple medical specialties, established brand portfolio, and global manufacturing footprint that enable reliable, integrated supply. Its goal is to improve patients’ lives worldwide by helping customers bring safe and effective medical technologies to market.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Wilmington, Delaware
Founded
1940
Get referred to Integer Holdings Corporation
See people who can refer or advise you
Simplify's Take
What believers are saying
- August 3, 2026 KKR deal prices Integer at $127, a 51.8% premium.
- Second-quarter 2026 revenue hit $464.1 million and adjusted EPS reached $1.60.
- KKR promised capacity, technology, and talent investment, plus employee ownership after closing.
What critics are saying
- KKR closing slips past year-end 2026 if antitrust or stockholder votes fail.
- Halper Sadeh's August 2026 investigation fuels litigation over fairness and disclosure.
- New Ross shutdown exposed demand volatility and labor pain; repeat interruptions threaten margins and credibility.
What makes Integer Holdings Corporation unique
- Integer's 2026 KKR sale confirms sticky device-manufacturing scale and regulatory know-how.
- Its CDMO footprint serves interventional cardiology, neuromodulation, and orthopedics across global customers.
- New Ross and other plants give Integer specialized capacity competitors cannot quickly replicate.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Adoption Assistance
Parental Leave
401(k) Company Match
401(k) Retirement Plan
Paid Vacation
Paid Holidays
Company News
Healthcare stocks have returned 26.1% over the past six months, outperforming the S&P 500 by 13.1 percentage points. However, investors must remain cautious due to heavy regulation affecting earnings potential. Integer Holdings faces concerns with 6.1% annual revenue growth over two years, lagging healthcare peers. Its modest revenue base of $1.84 billion provides less fixed cost leverage than larger competitors. The company trades at $125.07 per share, or 18.6 times forward price-to-earnings. Evolent Health shows weak platform performance and declining returns on capital. Its high net-debt-to-EBITDA ratio of 7 times could force unfavourable capital raises if market conditions worsen. Shares trade at $4.15, representing 12.4 times forward price-to-earnings. Tenet Healthcare, operating hospitals and surgical centres across nine US states, emerges as the recommended healthcare investment.
Integer Holdings agreed to be acquired by private equity firm KKR in an all-cash deal valued at approximately $5.7 billion. The transaction values the medical technology company at $127 per share. Shares jumped 2.7% in afternoon trading, continuing a rally from the previous session when the stock surged over 20% following the announcement. The acquisition news overshadowed strong second-quarter results, where Integer posted an adjusted profit of $1.60 per share on $464.1 million in revenue, surpassing analyst estimates. Following the buyout announcement, Integer withdrew its previously issued financial guidance and cancelled its upcoming earnings conference call. Shares traded at $124.50, marking a new 52-week high.
KKR has agreed to acquire Integer Holdings Corporation, a medical device contract development and manufacturing organisation, in an all-cash transaction valued at approximately $5.7 billion. Integer stockholders will receive $127 per share, representing a 51.8% premium to the company's closing share price on 29 April 2026. The acquisition follows a comprehensive strategic review announced by Integer in April 2026. The Integer Board unanimously approved the agreement and recommends stockholder approval. KKR plans to invest in Integer's capacity, technology, innovation, and talent. The firm also intends to establish a broad-based employee ownership programme following the transaction's close, consistent with its approach across portfolio companies. The transaction is expected to close by year-end, subject to stockholder approval and regulatory clearances. Upon completion, Integer will become privately held and delist from the New York Stock Exchange.
Integer Holdings Corp. reported second-quarter net income of $23.6 million, or 69 cents per share. Adjusted earnings came to $1.60 per share, exceeding Wall Street expectations of $1.38 per share. The Plano, Texas-based medical device outsource manufacturer posted revenue of $464.1 million for the period, also beating analyst forecasts of $452.5 million. The results surpassed predictions from five analysts surveyed by Zacks Investment Research on both earnings and revenue metrics.
KKR & Co Inc (NYSE: KKR) Acquires Integer Holdings Corporation (NYSE: ITGR): key insights into the medical device acquisition. Aug 03, 2026 Market News FMPKKR & Co Inc (NYSE: KKR) Acquires Integer Holdings Corporation (NYSE: ITGR):... * Integer Holdings Corporation (NYSE: ITGR) is being acquired by KKR (NYSE: KKR) for approximately $5.70 billion at $127.00 per share. * The acquisition price represents a 51.80% premium over Integer's closing price on April 29, 2026. * An investor rights law firm, Halper Sadeh LLC, is investigating the acquisition to ensure a fair price for shareholders and compliance with federal securities laws. Integer Holdings Corporation is a leading medical-device outsourcing company. It helps other companies develop and manufacture medical devices. On August 3, 2026, global investment firm KKR announced it will acquire Integer in a deal valued at an enterprise value of approximately $5.70 billion. An analyst at Truist Financial (NYSE: TFC) set a new price target for Integer at $127.00. This price target directly matches the $127.00 per share all-cash offer made by KKR for the acquisition. The acquisition follows a strategic review process conducted by Integer's board of directors. The analyst also downgraded the stock to a "Hold" rating. A "Hold" rating suggests that the stock's price is not expected to move much. This is common after an acquisition announcement, as the stock price tends to stay close to the agreed-upon purchase price until the deal is finalized. The $127.00 per share offer is a 51.80% premium over Integer's closing price on April 29, 2026. It is also a 28.80% premium to the 30-day volume-weighted average price (VWAP) as of July 31, 2026. VWAP is the average price a stock has traded at over a period, adjusted for trading volume. Despite the premium, an investor rights law firm, Halper Sadeh LLC, is investigating the sale. As highlighted by Business Wire, the firm is looking into whether Integer's board secured a fair price for its shareholders and followed federal securities laws during the process. Market news and analyst rating coverage Rayan Ahmad covers market news, analyst rating changes, and company developments for the FMP blog. His work focuses on summarizing price-target updates, earnings results, and broker actions into accessible, data-backed market updates. Financial data for every need. Real-time quotes and 30+ years of historical data, including prices, fundamentals, and insider transactions - all accessible via API. Stock Screener 2017-2026 (C) FMP